今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

致敬AI先驱：商汤科技创始人汤晓鸥教授逝世，享年55岁

北京讯 2023年12月16日，传来令人痛惜的消息，著名人工智能科学家、商汤科技创始人汤晓鸥教授因病逝世，享年55岁。

汤晓鸥教授出生于1968年，辽宁鞍山人。他是计算机视觉领域的领军人物，被誉为“AI之父”。他早年毕业于中国科学技术大学、美国罗切斯特大学和麻省理工学院，师从著名计算机科学家谭述之教授。

1996年获得博士学位后，汤晓鸥教授加入香港中文大学，创立了多媒体实验室。他主持开发了多项世界领先的人工智能技术，包括DeepID人脸识别算法，为我国人工智能产业发展做出了巨大贡献。

2014年，汤晓鸥教授创办商汤科技，带领团队将人工智能技术从实验室推向产业化，落地智慧城市、医疗、金融等多个领域，为人工智能的广泛应用奠定了基础。

汤晓鸥教授不仅是杰出的科学家，也是一位悉心育人的教育家。他曾培养了众多优秀人才，为中国人工智能人才队伍建设做出了重要贡献。

汤晓鸥教授的逝世，是人工智能领域的重大损失。他的离去，令所有热爱和尊敬他的人们深感悲痛。我们向汤晓鸥教授表示沉痛的哀悼，并向他的家人致以最诚挚的慰问。

汤晓鸥教授的贡献

汤晓鸥教授在计算机视觉领域做出了许多开创性的贡献，其主要成果包括：

• 开发了DeepID人脸识别算法，该算法将人脸识别准确率提升至99.55%，引领了人脸识别技术的发展。
• 创办商汤科技，将人工智能技术从实验室推向产业化，落地智慧城市、医疗、金融等多个领域。
• 培养了众多优秀人工智能人才，为中国人工智能人才队伍建设做出了重要贡献。

汤晓鸥教授的离去，是人工智能领域的重大损失。他的精神将激励着我们继续前行，为实现人工智能的更大发展而努力奋斗。

以下是一些对汤晓鸥教授的评价：

• “汤晓鸥教授是人工智能领域的领军人物，他的去世是行业的重大损失。”——中国工程院院士谭述之
• “汤晓鸥教授是一位杰出的科学家和教育家，他为中国人工智能事业的发展做出了巨大贡献。”——香港中文大学校长沈祖泽
• “汤晓鸥教授是一位充满理想和抱负的企业家，他为人工智能产业化做出了开创性的贡献。”——商汤科技董事长徐立

汤晓鸥教授的逝世，提醒我们，生命无常，要珍惜当下。让我们缅怀汤晓鸥教授，学习他的精神，为实现人工智能的更大发展而努力奋斗。